According to TipRanks.com, Friedrichs is ranked #3055 out of 7890 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $53.20 average price target, implying a 17.9% upside from current levels. In a report issued on April 20, DZ BANK AG also maintained a Buy rating on the stock.
Qiagen’s market cap is currently $10.2B and has a P/E ratio of 20.33.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN: